FDA takes rare step of revoking orphan drug status
The decision means that Indivior’s Sublocade is no longer eligible for lucrative exclusivity, but leaves concerns about evergreening unaddressed
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.